Comparative gene expression profiles induced by PPARγ and PPARα/γ agonists in rat hepatocytes

Toxicology and Applied Pharmacology

Volumn 254, Issue 1, 2011, Pages 18-31

  Rogue, Alexandra ^a,b,c   Renaud, Marie Pierre ^c   Claude, Nancy ^c   Guillouzo, André ^a,b   Spire, Catherine ^c  

^a FACULTÉ DES SCIENCES PHARMACEUTIQUES ET BIOLOGIQUES   (France)

^b UNIVERSITÉ DE RENNES 1   (France)

^c INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

Cryopreserved rat hepatocytes; Gene profiling; Glitazars; Glitazones; PPAR ; PPAR

Indexed keywords

MURAGLITAZAR; ROSIGLITAZONE; TESAGLITAZAR; TRANSCRIPTOME; TROGLITAZONE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; LIVER; LIVER CELL; MALE; NONHUMAN; QUANTITATIVE ANALYSIS; RAT;

RATTUS; RODENTIA;

EID: 79957970349     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2011.04.005     Document Type: Article

References (48)

1. Ammerschlaeger M., Beigel J., Klein K.U., Mueller S.O. Characterization of the species-specificity of peroxisome proliferators in rat and human hepatocytes. Toxicol. Sci. 2004, 78:229-240.
2. Brazma A., Hingamp P., Quackenbush J., Sherlock G., Spellman P., Stoeckert C., Aach J., Ansorge W., Ball C.A., Causton H.C., Gaasterland T., Glenisson P., Holstege F.C., Kim I.F., Markowitz V., Matese J.C., Parkinson H., Robinson A., Sarkans U., Schulze-Kremer S., Stewart J., Taylor R., Vilo J., Vingron M. Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat. Genet. 2001, 29:365-371.
3. Cariello N.F., Romach E.H., Colton H.M., Ni H., Yoon L., Falls J.G., Casey W., Creech D., Anderson S.P., Benavides G.R., Hoivik D.J., Brown R., Miller R.T. Gene expression profiling of the PPAR-alpha agonist ciprofibrate in the cynomolgus monkey liver. Toxicol. Sci. 2005, 88:250-264.
4. Cheon Y., Nara T.Y., Band M.R., Beever J.E., Wallig M.A., Nakamura M.T. Induction of overlapping genes by fasting and a peroxisome proliferator in pigs: evidence of functional PPARalpha in nonproliferating species. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2005, 288:R1525-R1535.
5. Cox P.J., Ryan D.A., Hollis F.J., Harris A.M., Miller A.K., Vousden M., Cowley H. Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans. Drug Metab. Dispos. 2000, 28:772-780.
6. Davies G.F., Khandelwal R.L., Roesler W.J. Troglitazone induces expression of PPARgamma in liver. Mol. Cell Biol. Res. Commun. 1999, 2:202-208.
7. DeLuca J.G., Doebber T.W., Kelly L.J., Kemp R.K., Molon-Noblot S., Sahoo S.P., Ventre J., Wu M.S., Peters J.M., Gonzalez F.J., Moller D.E. Evidence for peroxisome proliferator-activated receptor (PPAR)alpha-independent peroxisome proliferation: effects of PPARgamma/delta-specific agonists in PPARalpha-null mice. Mol. Pharmacol. 2000, 58:470-476.
8. Ericsson H., Hamren B., Bergstrand S., Elebring M., Fryklund L., Heijer M., Ohman K.P. Pharmacokinetics and metabolism of tesaglitazar, a novel dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist, after a single oral and intravenous dose in humans. Drug Metab. Dispos. 2004, 32:923-929.
9. Fievet C., Fruchart J.C., Staels B. PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome. Curr. Opin. Pharmacol. 2006, 6:606-614.
10. Fuentes L., Roszer T., Ricote M. Inflammatory mediators and insulin resistance in obesity: role of nuclear receptor signaling in macrophages. Mediators Inflamm. 2010, 2010:219583.
11. Funk C., Pantze M., Jehle L., Ponelle C., Scheuermann G., Lazendic M., Gasser R. Troglitazone-induced intrahepatic cholestasis by an interference with the hepatobiliary export of bile acids in male and female rats. Correlation with the gender difference in troglitazone sulfate formation and the inhibition of the canalicular bile salt export pump (Bsep) by troglitazone and troglitazone sulfate. Toxicology 2001, 167:83-98.
12. Goll V., Alexandre E., Viollon-Abadie C., Nicod L., Jaeck D., Richert L. Comparison of the effects of various peroxisome proliferators on peroxisomal enzyme activities, DNA synthesis, and apoptosis in rat and human hepatocyte cultures. Toxicol. Appl. Pharmacol. 1999, 160:21-32.
13. Gonzalez F.J. The peroxisome proliferator-activated receptor alpha (PPARalpha): role in hepatocarcinogenesis. Mol. Cell. Endocrinol. 2002, 193:71-79.
14. Gonzalez F.J., Shah Y.M. PPARalpha: mechanism of species differences and hepatocarcinogenesis of peroxisome proliferators. Toxicology 2008, 246:2-8.
15. Guo L., Zhang L., Sun Y., Muskhelishvili L., Blann E., Dial S., Shi L., Schroth G., Dragan Y.P. Differences in hepatotoxicity and gene expression profiles by anti-diabetic PPAR gamma agonists on rat primary hepatocytes and human HepG2 cells. Mol. Divers. 2006, 10:349-360.
16. Guo L., Fang H., Collins J., Fan X.H., Dial S., Wong A., Mehta K., Blann E., Shi L., Tong W., Dragan Y.P. Differential gene expression in mouse primary hepatocytes exposed to the peroxisome proliferator-activated receptor alpha agonists. BMC Bioinformatics 2006, 7(Suppl 2):S18.
17. Hellmold H., Zhang H., Andersson U., Blomgren B., Holland T., Berg A.L., Elebring M., Sjogren N., Bamberg K., Dahl B., Westerberg R., Dillner B., Tugwood J., Roberts R., Lundholm E., Camejo G., Skanberg I., Evans J. Tesaglitazar, a PPARalpha/gamma agonist, induces interstitial mesenchymal cell DNA synthesis and fibrosarcomas in subcutaneous tissues in rats. Toxicol. Sci. 2007, 98:63-74.
18. Isley W.L. Hepatotoxicity of thiazolidinediones. Expert Opin. Drug Saf. 2003, 2:581-586.
19. Lambert C.B., Spire C., Claude N., Guillouzo A. Dose- and time-dependent effects of phenobarbital on gene expression profiling in human hepatoma HepaRG cells. Toxicol. Appl. Pharmacol. 2009, 234:345-360.
20. Lauer B., Tuschl G., Kling M., Mueller S.O. Species-specific toxicity of diclofenac and troglitazone in primary human and rat hepatocytes. Chem. Biol. Interact. 2009, 179:17-24.
21. Lee Y.H., Chung M.C., Lin Q., Boelsterli U.A. Troglitazone-induced hepatic mitochondrial proteome expression dynamics in heterozygous Sod2(+/-) mice: two-stage oxidative injury. Toxicol. Appl. Pharmacol. 2008, 231:43-51.
22. Li J., Kaneko T., Wang Y., Qin L.Q., Wang P.Y., Sato A. Troglitazone enhances the hepatotoxicity of acetaminophen by inducing CYP3A in rats. Toxicology 2002, 176:91-100.
23. Loi C.M., Young M., Randinitis E., Vassos A., Koup J.R. Clinical pharmacokinetics of troglitazone. Clin. Pharmacokinet. 1999, 37:91-104.
24. Memon R.A., Tecott L.H., Nonogaki K., Beigneux A., Moser A.H., Grunfeld C., Feingold K.R. Up-regulation of peroxisome proliferator-activated receptors (PPAR-alpha) and PPAR-gamma messenger ribonucleic acid expression in the liver in murine obesity: troglitazone induces expression of PPAR-gamma-responsive adipose tissue-specific genes in the liver of obese diabetic mice. Endocrinology 2000, 141:4021-4031.
25. Perrone C.E., Shao L., Williams G.M. Effect of rodent hepatocarcinogenic peroxisome proliferators on fatty acyl-CoA oxidase, DNA synthesis, and apoptosis in cultured human and rat hepatocytes. Toxicol. Appl. Pharmacol. 1998, 150:277-286.
26. Rachek L.I., Yuzefovych L.V., Ledoux S.P., Julie N.L., Wilson G.L. Troglitazone, but not rosiglitazone, damages mitochondrial DNA and induces mitochondrial dysfunction and cell death in human hepatocytes. Toxicol. Appl. Pharmacol. 2009, 240:348-354.
27. Rakhshandehroo M., Hooiveld G., Muller M., Kersten S. Comparative analysis of gene regulation by the transcription factor PPARalpha between mouse and human. PLoS One 2009, 4:e6796.
28. Richert L., Price S., Chesne C., Maita K., Carmichael N. Comparison of the induction of hepatic peroxisome proliferation by the herbicide oxadiazon in vivo in rats, mice, and dogs and in vitro in rat and human hepatocytes. Toxicol. Appl. Pharmacol. 1996, 141:35-43.
29. Richert L., Lamboley C., Viollon-Abadie C., Grass P., Hartmann N., Laurent S., Heyd B., Mantion G., Chibout S.D., Staedtler F. Effects of clofibric acid on mRNA expression profiles in primary cultures of rat, mouse and human hepatocytes. Toxicol. Appl. Pharmacol. 2003, 191:130-146.
30. Ricote M., Li A.C., Willson T.M., Kelly C.J., Glass C.K. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998, 391:79-82.
31. Rogue A., Spire C., Brun M., Claude N., Guillouzo A. gene expression changes induced by PPAR gamma agonists in animal and human liver. PPAR Res. 2010, 2010:325183.
32. Rogue, A., Lambert, C.B., Josse, R., Antherieu, S., Spire, C., Claude, N., Guillouzo, A., 2011. Comparative gene expression profiles induced by PPARγ and PPARα/γ agonists in human hepatocytes. PLoS ONE, 6(4), e18816.
33. Rubenstrunk A., Hanf R., Hum D.W., Fruchart J.C., Staels B. Safety issues and prospects for future generations of PPAR modulators. Biochim. Biophys. Acta 2007, 1771:1065-1081.
34. Sahi J., Hamilton G., Sinz M., Barros S., Huang S.M., Lesko L.J., LeCluyse E.L. Effect of troglitazone on cytochrome P450 enzymes in primary cultures of human and rat hepatocytes. Xenobiotica 2000, 30:273-284.
35. Sahi J., Black C.B., Hamilton G.A., Zheng X., Jolley S., Rose K.A., Gilbert D., LeCluyse E.L., Sinz M.W. Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Drug Metab. Dispos. 2003, 31:439-446.
36. Schadinger S.E., Bucher N.L., Schreiber B.M., Farmer S.R. PPARgamma2 regulates lipogenesis and lipid accumulation in steatotic hepatocytes. Am. J. Physiol. Endocrinol. Metab. 2005, 288:E1195-E1205.
37. Seimandi M., Lemaire G., Pillon A., Perrin A., Carlavan I., Voegel J.J., Vignon F., Nicolas J.C., Balaguer P. Differential responses of PPARalpha, PPARdelta, and PPARgamma reporter cell lines to selective PPAR synthetic ligands. Anal. Biochem. 2005, 344:8-15.
38. Shan W., Palkar P.S., Murray I.A., McDevitt E.I., Kennett M.J., Kang B.H., Isom H.C., Perdew G.H., Gonzalez F.J., Peters J.M. Ligand activation of peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) attenuates carbon tetrachloride hepatotoxicity by downregulating proinflammatory gene expression. Toxicol. Sci. 2008, 105:418-428.
39. Sigrist S., Bedoucha M., Boelsterli U.A. Down-regulation by troglitazone of hepatic tumor necrosis factor-alpha and interleukin-6 mRNA expression in a murine model of non-insulin-dependent diabetes. Biochem. Pharmacol. 2000, 60:67-75.
40. Smith M.T. Mechanisms of troglitazone hepatotoxicity. Chem. Res. Toxicol. 2003, 16:679-687.
41. Tamura K., Ono A., Miyagishima T., Nagao T., Urushidani T. Profiling of gene expression in rat liver and rat primary cultured hepatocytes treated with peroxisome proliferators. J. Toxicol. Sci. 2006, 31:471-490.
42. Tannehill-Gregg S.H., Sanderson T.P., Minnema D., Voelker R., Ulland B., Cohen S.M., Arnold L.L., Schilling B.E., Waites C.R., Dominick M.A. Rodent carcinogenicity profile of the antidiabetic dual PPAR alpha and gamma agonist muraglitazar. Toxicol. Sci. 2007, 98:258-270.
43. Vansant G., Pezzoli P., Saiz R., Birch A., Duffy C., Ferre F., Monforte J. Gene expression analysis of troglitazone reveals its impact on multiple pathways in cell culture: a case for in vitro platforms combined with gene expression analysis for early (idiosyncratic) toxicity screening. Int. J. Toxicol. 2006, 25:85-94.
44. Waites C.R., Dominick M.A., Sanderson T.P., Schilling B.E. Nonclinical safety evaluation of muraglitazar, a novel PPARalpha/gamma agonist. Toxicol. Sci. 2007, 100:248-258.
45. Willson T.M., Brown P.J., Sternbach D.D., Henke B.R. The PPARs: from orphan receptors to drug discovery. J. Med. Chem. 2000, 43:527-550.
46. Yamamoto Y., Nakajima M., Yamazaki H., Yokoi T. Cytotoxicity and apoptosis produced by troglitazone in human hepatoma cells. Life Sci. 2001, 70:471-482.
47. Yu S., Matsusue K., Kashireddy P., Cao W.Q., Yeldandi V., Yeldandi A.V., Rao M.S., Gonzalez F.J., Reddy J.K. Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor gamma1 (PPARgamma1) overexpression. J. Biol. Chem. 2003, 278:498-505.
48. Zhang D., Wang L., Raghavan N., Zhang H., Li W., Cheng P.T., Yao M., Zhang L., Zhu M., Bonacorsi S., Yeola S., Mitroka J., Hariharan N., Hosagrahara V., Chandrasena G., Shyu W.C., Humphreys W.G. Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. Drug Metab. Dispos. 2007, 35:150-167.